Recombinant Human Anti-RSV Antibody (D25)

Customer Review

There are currently no Customer reviews or questions for PABL-322. Click the button above to contact us or submit your feedback about this product.

Jessica Hill
22.Feb,23

Excellent for RSV Research

The Anti-RSV Antibody has been excellent for our RSV detection assays. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

David Adams
29.May,22

Reliable in Immunoassays

We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for RSV is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Megan Martinez
13.Aug,21

Consistent High-Quality Results

This antibody has proven to be consistent and reliable in our assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for RSV have been particularly beneficial.

User 193*****49
03.Mar,24

Highly Sensitive for RSV Detection in ELISA

We've been using the Recombinant Human Anti-RSV Antibody (D25) (CAT#: PABL-322) from Creative Biolabs in our ELISA assays, and it has provided excellent results. The antibody is highly sensitive, allowing us to detect even low levels of RSV with great accuracy. We've had minimal background noise, and the results are consistently reproducible across different batches. It has been especially useful for screening samples in our respiratory syncytial virus (RSV) research.

Q&As

1. Is the anti-RSV antibody suitable for use in Western blotting?

   A: Yes, the anti-RSV antibody (PABL-322) is suitable for use in Western blotting. It provides specific binding to the RSV protein, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-RSV antibody?

   A: The recommended storage condition for the anti-RSV antibody (PABL-322) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-RSV antibody be used in immunoprecipitation assays?

   A: Yes, the anti-RSV antibody (PABL-322) can be used in immunoprecipitation assays. It provides specific binding to the RSV protein, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-RSV antibody effective in ELISA applications?

   A: Yes, the anti-RSV antibody (PABL-322) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of the RSV protein.

5. What is the optimal dilution for using the anti-RSV antibody in immunofluorescence?

   A: The optimal dilution for using the anti-RSV antibody (PABL-322) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Tang, Wei, et al. "Mechanism of cross-resistance to fusion inhibitors conferred by the K394R mutation in respiratory syncytial virus fusion protein." Journal of Virology 95.20 (2021): 10-1128. https://doi.org/10.1128/jvi.01205-21
   This study investigates the mechanism of cross-resistance to fusion inhibitors conferred by the K394R mutation in the respiratory syncytial virus (RSV) fusion protein. The researchers employed a dual-luciferase protocol to discover LF-6, a small-molecule inhibitor that targets the RSV fusion glycoprotein. They found that the K394R mutation not only conferred resistance to LF-6 but also to other RSV fusion inhibitors, including those in clinical development. This mutation destabilizes the F protein and enhances its membrane fusion activity, increasing viral resistance. The study highlights the need for alternative strategies to combat RSV infections, given the resistance risks posed by the K394R mutation.
   In this research, Creative Biolabs provided crucial reagents that facilitated the experiments. Specifically, the D25 monoclonal antibody (Cat# PABL-322) and Motavizumab (Cat# TAB-709) were used for detecting RSV F protein in various assays, including the immunofluorescence and cell-surface triggering assays. These antibodies were essential for accurately identifying the effects of mutations on the RSV F protein and assessing the resistance mechanisms. The products from Creative Biolabs significantly contributed to the detailed analysis and validation of the findings related to the K394R mutation and its impact on RSV fusion inhibitor resistance​.
2. Gilbert, Brian E., et al. "Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge." Vaccine 36.52 (2018): 8069-8078. https://doi.org/10.1016/j.vaccine.2018.10.073
   This study focused on the development and evaluation of an RSV F nanoparticle vaccine targeting human respiratory syncytial virus (RSV), which is a major cause of severe respiratory infections in various vulnerable populations, including newborns and the elderly. The RSV F nanoparticle vaccine was designed to induce a broad polyclonal antibody response against multiple neutralizing epitopes on the fusion (F) protein of RSV. These antibodies were shown to neutralize both wild-type RSV and palivizumab-resistant mutant strains in animal models, particularly in cotton rats. The vaccine's efficacy was enhanced with the use of an aluminum phosphate adjuvant, which significantly increased the antibody avidity and protection against RSV challenges.
   Creative Biolabs contributed to this study by providing the monoclonal antibody D25 (Cat#: PABL-322), which was used for competitive binding assays to characterize the antibody responses elicited by the RSV F nanoparticle vaccine. The D25 antibody specifically targets antigenic site Ø on the pre-fusion F conformation of the RSV F protein. The inclusion of this antibody was crucial for demonstrating that the vaccine-induced antibodies could bind to conserved epitopes on both pre-fusion and post-fusion F conformations, supporting the vaccine's potential to provide broad protection against RSV.
3. Lee, Youri, et al. "The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants." Antiviral research 168 (2019): 100-108. https://doi.org/10.1016/j.antiviral.2019.05.011
   This study investigates the efficacy of inactivated split respiratory syncytial virus (RSV) as a vaccine candidate compared to traditional formalin-inactivated RSV (FI-RSV). The research demonstrates that split RSV, created by treating FI-RSV with detergent, displays higher reactivity against neutralizing antibodies in vitro and causes less histopathology in mice after challenge. Furthermore, when combined with monophosphoryl lipid A (MPL) and CpG adjuvants, the split RSV vaccine effectively increases T helper type 1 immune responses, enhances IgG2a isotype antibodies and neutralizing activity, promotes lung viral clearance, and prevents pulmonary histopathology after vaccination and challenge in a two-week-old mouse model.
   Creative Biolabs provided the D25 monoclonal antibody that specifically recognizes the pre-fusion conformation of the RSV F protein. This antibody was crucial for analyzing the antigenic properties of the split RSV vaccine, enabling researchers to demonstrate that detergent treatment enhanced the exposure of neutralizing epitopes. These findings provided a mechanistic explanation for the improved efficacy and reduced pathology of the split RSV vaccine formulation, potentially advancing the development of safer and more effective RSV vaccines.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# PABL-322, RRID: AB_3111649)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Publications

Our products have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of publications that cite this product.

Gilbert, Brian E., et al. "Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge." Vaccine 36.52 (2018): 8069-8078.

Lee, Youri, et al. "The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants." Antiviral research (2019)

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

See other products for "Clone D25"

See other products for "RSV"

Select a product category from the dropdown menu below to view related products.